AIM Immunotech vs Lisata Therapeutics
Lisata Therapeutics is the larger business, with $170,000 of revenue in fiscal 2025 against $88,000 for AIM Immunotech (1.9 times as much). AIM Immunotech grew faster (-48.2% against -83.0%). Lisata Therapeutics kept more of each dollar of sales as profit: a net margin of -9756.5% against -15861.4%.
| Latest fiscal year | AIM ImmunotechAIM, 2025 | Lisata TherapeuticsLSTA, 2025 |
|---|---|---|
| Revenue | $88,000 | $170,000 |
| Revenue growth | -48.2% | -83.0% |
| Net income | −$14.0m | −$16.6m |
| Operating margin | -13254.5% | -10711.2% |
| Net margin | -15861.4% | -9756.5% |
| Return on equity | — | -74.7% |
| Free cash flow | −$11.0m | −$16.0m |
| Cash | $3.0m | $16.0m |
| Total debt | $8.0m | $0 |
| Debt to equity | — | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 19 | 21 |
| Market value | $4.7m | $9.8m |
| Price vs our value range | — | — |
| Moat score | 5 (Weak) | 5 (Weak) |
| Insider trades, 12 months | 6 buys, 0 sales | 0 buys, 0 sales |